Search Results 311-320 of 16787 for GLP-1 agonists
Use of any glucagon-like peptide-1 (GLP-1) agonists (e.g., exenatide, liraglutide, lixisenatide, albiglutide, and dulaglutide) within 90 days before Day 1.
... 1 trial. Phase 4 trials look at long-term safety and effectiveness, after ... * Participants on a glucagon-like peptide-1 (GLP-1) agonist must be on a ...
The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and may or may not be on ...
About this study. The purpose of this research is to create a single registry for type 1 and type 2 diabetes at Mayo Rochester and affiliated Mayo sites.
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Adagrasib; Adenovirus Vaccine Type ...
* Subjects in the non-pancreatic disease subgroup (i.e., T2DM) on longer acting agents, including thiazolidinediones and once-weekly GLP-1 agonists ...
These medicines mimic the effects of dopamine. Dopamine is the brain chemical that controls how much prolactin the pituitary gland makes. Dopamine agonists can ...
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s. ... November 1, ...
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Succinylcholine. Other ...
The purpose of this study is to collect blood samples for biomarker assessment in type 1 diabetes prior to and at specific time points during closed loop ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!